Confusion surrounding Phase III data for a myelodysplastic syndrome candidate named Dacogen caused SuperGen Inc.'s stock to dive, despite the firm's contention that the data are positive. Read More
It may have been a day filled with pranks, cranks and guffaws, but there was no fooling around at Santarus Inc.'s offices in San Diego on Thursday. The company celebrated April 1 by raising $54 million in its initial public offering, pricing 6 million shares at $9 each. (BioWorld Today) Read More
